Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 11/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26108847 | 0.90 | TOP1 (0.72) | TOP1SLC2A1 | |
| SCHEMBL24642412 | 0.86 | TOP1 (0.55) | TOP1HDAC3HDAC1HDAC6 | |
| SCHEMBL31317625 | 0.86 | TOP1 (0.55) | TOP1HDAC3HDAC1HDAC6 | |
| SCHEMBL31538097 | 0.86 | TOP1 (0.55) | TOP1HDAC3HDAC1HDAC6 | |
| SCHEMBL9563444 | 0.85 | TOP1 (0.73) | TOP1SLC2A1 | |
| SCHEMBL24642901 | 0.85 | TOP1 (0.68) | TOP1SLC2A1 | |
| SCHEMBL29323278 | 0.84 | TOP1 (0.64) | TOP1HDAC3HDAC1HDAC6 | |
| SCHEMBL5960183 | 0.84 | HDAC6 (0.59) | HDAC3HDAC1HDAC6 | |
| SCHEMBL29322803 | 0.83 | TOP1 (0.65) | TOP1HDAC3HDAC1HDAC6SLC2A1 | |
| SCHEMBL7629080 | 0.83 | HDAC3 (0.59) | TOP1HDAC3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | TOP1 3533/4885HDAC3 4136/4885HDAC1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.